Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 0.40 |
| ▸ | PGR | P06401 | 4/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31467853 | 0.99 | AR (0.40) | ARPGRNR3C2NR3C1KDM4E | |
| SCHEMBL31565383 | 0.87 | AR (0.37) | ARKDM4EUSP2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL29913721 | 0.85 | AR (0.36) | ARKDM4EUSP2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL31467790 | 0.81 | ALDH1A1 (0.38) | ARKDM4EUSP2ALDH1A1 | |
| SCHEMBL27169508 | 0.76 | HRH1 (0.43) | ARPGRNR3C2NR3C1 | |
| SCHEMBL27169505 | 0.76 | HRH1 (0.43) | ARPGRNR3C2NR3C1 | |
| SCHEMBL22661404 | 0.75 | IMPDH2 (0.55) | ARKDM4EUSP2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30872806 | 0.75 | HRH1 (0.42) | ARPGRNR3C2NR3C1 | |
| SCHEMBL31565401 | 0.74 | AR (0.47) | ARPGRNR3C2NR3C1 | |
| SCHEMBL26801814 | 0.74 | AR (0.49) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129070-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. | 2025-04-24 | — | — | US | disclosed |
| WO-2025081082-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | KOLM THERAPEUTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129070-A1 | BIFUNCTIONAL ANDROGEN RECEPTOR COMPOUNDS | AR, SHBG, FSHR | AR 1/4885PGR 73/4885NR3C2 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.